Why PFAS Don’t Leave: The Biochemistry of Bioaccumulation
The phrase “forever chemicals” captures a key property of PFAS: they persist in the human body for years to decades, with blood half-lives that dwarf those of virtually all other anthropogenic chemicals. Understanding why PFAS bioaccumulate—the biochemical and physiological mechanisms that allow these compounds to resist elimination—is foundational to understanding why regulatory standards must be extremely stringent and why the window for preventing health effects is limited once exposure occurs.
The C-F Bond: Chemistry’s Most Stable
PFAS resistance to biological degradation begins with their chemistry. The carbon-fluorine (C-F) bond is the strongest in organic chemistry—with bond dissociation energies of 130 kcal/mol, compared to 99 kcal/mol for carbon-hydrogen bonds. This extraordinary stability means that enzymatic degradation pathways that break down most organic chemicals—oxidation by cytochrome P450 enzymes, hydrolysis, photodegradation—cannot cleave the C-F bond under physiological conditions. PFAS that enter the body cannot be metabolized to non-PFAS compounds through normal biotransformation pathways. Terminal perfluorinated acids like PFOA and PFOS are therefore absorbed, distributed, and eventually eliminated only through excretion—a process that is extremely slow for the most persistent compounds.
Serum Protein Binding: Why PFAS Concentrate in Blood
PFAS preferentially bind to serum albumin—the most abundant protein in human blood—and to other serum proteins including beta-lipoproteins and fatty acid-binding proteins. This protein binding is structurally analogous to the binding of fatty acids (PFAS mimic fatty acids due to their hydrophobic fluorocarbon tail and polar carboxylate or sulfonate head group). Protein binding serves several functions in PFAS toxicokinetics: it concentrates PFAS in blood at levels far above what passive distribution would achieve; it delays renal filtration and excretion by keeping PFAS bound to large protein molecules that cannot pass the glomerular filter; and it facilitates PFAS distribution to organs with high serum protein perfusion rates—particularly liver and kidney. Blood albumin concentrations therefore serve as a major determinant of PFAS body burden in human populations.
Half-Lives: Years to Decades of Persistence
Human serum elimination half-lives for key PFAS compounds: PFOS: 4.1–5.4 years (longest of major PFAS); PFOA: 3.5–3.8 years; PFNA: 2.7–3.1 years; PFHxS: 5.3–8.5 years (surprisingly long for a C6 compound); PFBS: 26 days (much shorter due to less avid protein binding). These half-lives mean that a person exposed to PFOS in drinking water retains detectable blood PFOS for 20+ years after exposure ceases—and that fetuses accumulate PFAS transferred from maternal circulation during pregnancy, with measurable blood PFAS at birth that reflect the mother’s lifetime exposure history. The long half-life of PFOS and PFHxS means that exposure assessments based on single blood measurements substantially underestimate lifetime cumulative exposure.
Breast Milk Transfer and Infant Exposure
PFAS transfer from maternal serum into breast milk at concentrations that reflect maternal blood burden—typically 1–5% of maternal serum concentration for most PFAS. While this transfer fraction is small, the combination of maternal blood PFAS levels in exposed populations with infant’s higher daily milk intake (relative to body weight) compared to adults creates significant infant PFAS exposure through breast milk. A 2022 study in the Faroe Islands found that breastfed infants had blood PFAS concentrations 2–4 times higher than formula-fed infants by 18 months of age. The WHO and pediatric health organizations globally recommend continued breastfeeding despite PFAS concerns—the benefits of breastfeeding for infant health substantially outweigh PFAS exposure risks—but the finding underscores the importance of eliminating maternal PFAS exposure from drinking water sources before and during pregnancy.
The biochemistry of PFAS bioaccumulation explains why drinking water exposure at even low concentrations—sustained over years—creates meaningful body burdens, and why early-life prevention of PFAS exposure through certified water filtration is more effective than post-exposure mitigation.